A subgroup analysis was conducted based on factors such as age, sex, systolic BP, diabetes, atrial fibrillation, valvular heart disease, chronic kidney disease, malignancy, CCI, and medication use, including renin–angiotensin–aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (Figure 3). This evidence concerns the gene NR3C2 and chronic kidney disease.